USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
Saved in:
| Main Authors | , |
|---|---|
| Format | Patent |
| Language | Croatian English |
| Published |
04.09.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse. |
|---|---|
| AbstractList | The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse. |
| Author | Bymaster, Frank McKinney, Anthony Alexander |
| Author_xml | – fullname: McKinney, Anthony Alexander – fullname: Bymaster, Frank |
| BookMark | eNqNjLsKwjAUQDvo4OsfAi4tGulDP-Aab0mgvZHkCtZFROIkVdBNnP1tFfwAp7Occ_pRp720oRe9Nh6FLUWcuenCJzKeJDKTMcFas4YKSeayqRJZSNjB0qhGVfZRzLJZ-tS4BUJhSLBGwQ6BayT-3pSllWFjyQsoS1SMK7FsRG3JQm0-EeHGWXZAvjbM6Pww6p4O51sY_TiIxiWy0jJcL_twux6OoQ33vXbrPM3TdJ7PmbPiP-sNiulABA |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| DocumentTitleAlternate | UPORABA (1R,5S)-(+)-1-(NAFTALEN-2-IL)-3-AZABICIKLO(3.1.0)HEKSANA U LIJEČENJU UVJETA KOJI SU POD UTJECAJEM MONOAMINSKIH NEUROTRANSMITERA |
| ExternalDocumentID | HRP20200424TT1 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_HRP20200424TT13 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 14:17:36 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | Croatian English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_HRP20200424TT13 |
| Notes | Application Number: HR2020P000424T |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200904&DB=EPODOC&CC=HR&NR=P20200424T1 |
| ParticipantIDs | epo_espacenet_HRP20200424TT1 |
| PublicationCentury | 2000 |
| PublicationDate | 20200904 |
| PublicationDateYYYYMMDD | 2020-09-04 |
| PublicationDate_xml | – month: 09 year: 2020 text: 20200904 day: 04 |
| PublicationDecade | 2020 |
| PublicationYear | 2020 |
| RelatedCompanies | Otsuka America Pharmaceutical, Inc |
| RelatedCompanies_xml | – name: Otsuka America Pharmaceutical, Inc |
| Score | 3.2913556 |
| Snippet | The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200904&DB=EPODOC&locale=&CC=HR&NR=P20200424T1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LTwIxEG6IGvWmqPGBpomGQLQI-4DdAzGl281ioEuWYsALkX1EYwIEMB6MZ_-2sw2IJ259pJN0mnm1M18RuqmElmUbpk7scjWGAKUcE7uW2CSM9CRK7GpkKZCktqh6PeOxb_Yz6H1VC6NwQj8VOCJIVAjyvlD6erq-xHJUbuX8fvQGQ5MHV9ad_DI6Tq_64dCdRp13fMdnecbqXpAXQb2jJg3NkBAqbad-dAq0z58aaVnK9L9NcQ_QTgfIjReHKPM6y6I9tvp6LYt228sXb2guhW9-hH56XY59FxcqwZ3ZLZLCbREis4KgHU96tMUF0cigVSQ6oc-00WQD1vK_9FKlVP72eJ8KjpsCS49jGXAqUxD_lBrzhdNUtcSYui5noMlwY4BB1fq03YRFIk32kwEVXVBz4Px2j9G1yyXzCOxo-Me_oResdy8r-gnaGk_G8SnC1TgKozgJTb0WGmD4R9A3Yy3WwQ_TXmrWGcptonS-efoC7ac9lZBl5NDWYvYRX4IFX4yuFOd_AdIOlHE |
| link.rule.ids | 230,309,786,891,25594,76903 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA8yxfnmJ34bUMaGZm5ru64PQ7I0JdUuHV0mmy_DtR2KsIlOfBCf_be9hvnxtLckRw6S4-7yS-4uCJ1V40bDMS2DOJV6CgClkhLHHjskToxxMnbqSUMXSWrLuuiZ132rv4SefnJhdJ3Qd10cETQqBn2faXv9_HeJ5erYytfL0SMMTa881XQLc3ScXfWD0N1Wk3dCN2QFxpoiKsio2dFEs2YqgErLNmBCjZVuW1layvN_n-Kto5UOsJvMNtDSw8smyrOfr9c20Wp7_uINzbnyvW6hr16X49DDxWp0YXVLpHheAmRWlLQjlKABl6RGBkGJGITe0ZbPBiwIP4xytVz5FLxPJce-xEpwrCJOVVbEP-PGQun6OpcYU8_jDCwZbg0wmNqQtn2YJLNgPxVR2QUzB4ff7jY69bhigsCKhr_7NxTR3-pV1dhBucl0ku4iXE-TOEnHsWXYsQmOfwR9K62lBpzDavd2Yw8dLuK0v5h8gvJCtYNh4MubA7SWUXRwlnmIcrOXt_QIvPlsdKyl8A3ok5db |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=USE+OF+%281R%2C5S%29-%28%2B%29-1-%28NAPHTHALEN-2-YL%29-3-AZABICYCLO%7B3.1.0%7DHEXANE+IN+THE+TREATMENT+OF+CONDITIONS+AFFECTED+BY+MONOAMINE+NEUROTRANSMITTERS&rft.inventor=McKinney%2C+Anthony+Alexander&rft.inventor=Bymaster%2C+Frank&rft.date=2020-09-04&rft.externalDBID=T1&rft.externalDocID=HRP20200424TT1 |